Illumina, Inc. (NASDAQ:ILMN) Receives $167.70 Consensus PT from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has received a consensus recommendation of “Hold” from the nineteen research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $167.70.

ILMN has been the topic of several research reports. TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective on the stock. in a report on Thursday, January 4th. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, April 10th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Barclays boosted their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Finally, OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th.

Illumina Stock Performance

Shares of ILMN opened at $122.87 on Friday. The company has a market capitalization of $19.57 billion, a PE ratio of -16.74 and a beta of 1.19. Illumina has a one year low of $89.00 and a one year high of $228.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The company’s fifty day moving average price is $132.44 and its 200 day moving average price is $127.54.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 EPS. As a group, analysts expect that Illumina will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of Illumina stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Illumina

A number of large investors have recently modified their holdings of the stock. Bouvel Investment Partners LLC lifted its position in shares of Illumina by 1.3% during the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after purchasing an additional 84 shares in the last quarter. STF Management LP lifted its position in shares of Illumina by 3.5% during the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after purchasing an additional 90 shares in the last quarter. Global Retirement Partners LLC raised its stake in shares of Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after buying an additional 94 shares during the last quarter. Gulf International Bank UK Ltd raised its stake in shares of Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after buying an additional 98 shares during the last quarter. Finally, Eukles Asset Management raised its stake in shares of Illumina by 1.7% during the third quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock worth $816,000 after buying an additional 100 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.